Denosumab, an anti-RANKL (receptor activator of nuclear factor kappa-B ligand) antibody that inhibits osteoclast differentiation and function, is considered to be a possible treatment for OI in a number of recently completed clinical trials (NCT03638128 and NCT02352753). This evidence concerns the gene TNFSF11 and osteogenesis imperfecta.